Article

Neuroprotectants show positive effect on RGCs in rat model of glaucoma

Erythropoietin (EPO), ciliary neurotrophic factor (CNTF), and wolfberry seem to provide neuroprotection of retinal ganglion cells in a rat model of ocular hypertension, according to Kwoh-fai So, PhD, chairman of the Department of Anatomy, University of Hong Kong.

Erythropoietin (EPO), ciliary neurotrophic factor (CNTF), and wolfberry seem to provide neuroprotection of retinal ganglioncells in a rat model of ocular hypertension, according to Kwoh-fai So, PhD, chairman of the Department of Anatomy, Universityof Hong Kong.

Dr. So and colleagues created a rat model of ocular hypertension in which the retinal ganglion cells were affected, andtested EPO, CNTF, and wolfberry, a Chinese herb, in three separate experiments.

All three seemed to be neuroprotective of the retinal ganglion cells.

"Endogenous EPO seems to have a recovery mechanism after retinal injury and the retinal ganglion cells might be rescued byendogenous EPO," Dr. So said. "CNTF enhanced regeneration and is an effective neurotrophic factor in protecting retinalganglion cells in the rat model.

"Wolfberry is very interesting to us because it improves visual acuity, benefits the liver and kidney, and adjusts the body'simmunity and also was protective of retinal ganglion cells in this rat model," Dr. So said. "Wolfberry might be a usefultreatment because it is a safe herbal medicine that has been used for a long time."

Investigators also are studying the effect of wolfberry on microglia.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.